Effect	effect	O	O	O	O
of	of	O	O	O	O
glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
on	on	O	O	O	O
the	the	O	O	O	O
sphincter	sphincter	O	O	O	O
of	of	O	O	O	O
Oddi	oddi	O	O	O	O
spasm	spasm	O	DISEASE	OTHERS	I
evoked	evoked	O	O	O	O
by	by	O	O	O	O
prostigmine-morphine	prostigmine-morphine	O	O	O	O
administration	administration	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
on	on	O	O	O	O
the	the	O	O	O	O
prostigmine-morphine-induced	prostigmine-morphine-induced	O	O	O	O
sphincter	sphincter	O	O	O	O
of	of	O	O	O	O
Oddi	oddi	O	O	O	O
spasm	spasm	O	DISEASE	OTHERS	I
was	was	O	O	O	O
evaluated	evaluated	O	O	O	O
in	in	O	O	O	O
nine	nine	O	O	O	O
female	female	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
sphincter	sphincter	O	O	OTHERS	I
of	of	O	O	OTHERS	I
Oddi	oddi	O	O	OTHERS	I
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

METHOD	method	O	O	O	O
:	:	O	O	O	O
Sphincter	sphincter	O	O	O	O
of	of	O	O	O	O
Oddi	oddi	O	O	O	O
spasm	spasm	O	DISEASE	OTHERS	I
was	was	O	O	O	O
induced	induced	O	O	O	O
by	by	O	O	O	O
prostigmine-morphine	prostigmine-morphine	O	O	O	O
administration	administration	O	O	O	O
(	(	O	O	O	O
0.5	0.5	O	O	O	O
mg	mg	O	O	OTHERS	I
prostigmine	prostigmine	O	O	OTHERS	I
intramuscularly	intramuscularly	O	O	O	O
and	and	O	O	O	O
10	10	O	O	O	O
mg	mg	O	O	OTHERS	I
morphine	morphine	CHEMICALS	O	OTHERS	I
subcutaneously	subcutaneously	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
visualized	visualized	O	O	O	O
by	by	O	O	O	O
quantitative	quantitative	O	O	O	O
hepatobiliary	hepatobiliary	O	O	O	O
scintigraphy	scintigraphy	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
entire	entire	O	O	O	O
procedure	procedure	O	O	O	O
was	was	O	O	O	O
repeated	repeated	O	O	O	O
during	during	O	O	O	O
glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
infusion	infusion	O	O	O	O
(	(	O	O	O	O
Nitrolingual	nitrolingual	O	O	OTHERS	I
1	1	O	O	O	O
microg/kg/min	microg/kg/min	O	O	O	O
for	for	O	O	O	O
120	120	O	O	O	O
min	min	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Prostigmine-morphine	prostigmine-morphine	O	O	O	O
provocation	provocation	O	O	O	O
caused	caused	O	O	O	O
significant	significant	O	O	O	O
increases	increases	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
time	time	O	O	O	O
to	to	O	O	O	O
peak	peak	O	O	O	O
activity	activity	O	O	O	O
(	(	O	O	O	O
Tmax	tmax	O	O	O	O
)	)	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
hepatic	hepatic	O	O	O	O
hilum	hilum	O	O	O	O
(	(	O	O	O	O
HH	hh	O	O	O	O
:	:	O	O	O	O
34.33	34.33	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
5.05	5.05	O	O	O	O
vs.	vs.	O	O	O	O
22.77	22.77	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
3.26	3.26	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
common	common	O	O	O	O
bile	bile	O	O	O	O
duct	duct	O	O	O	O
(	(	O	O	O	O
CBD	cbd	O	O	O	O
:	:	O	O	O	O
60.44	60.44	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
5.99	5.99	O	O	O	O
vs.	vs.	O	O	O	O
40.0	40.0	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
2.88	2.88	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
half-time	half-time	O	O	O	O
of	of	O	O	O	O
excretion	excretion	O	O	O	O
(	(	O	O	O	O
T1/2	t1/2	O	O	O	O
)	)	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
liver	liver	O	O	O	O
parenchyma	parenchyma	O	O	O	O
(	(	O	O	O	O
LP	lp	O	O	O	O
:	:	O	O	O	O
120.04	120.04	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
16.01	16.01	O	O	O	O
vs.	vs.	O	O	O	O
27.37	27.37	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
2.19	2.19	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
HH	hh	O	O	O	O
(	(	O	O	O	O
117.61	117.61	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
14.71	14.71	O	O	O	O
vs.	vs.	O	O	O	O
31.85	31.85	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
3.99	3.99	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
CBD	cbd	O	O	O	O
(	(	O	O	O	O
158.11	158.11	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
9.18	9.18	O	O	O	O
vs.	vs.	O	O	O	O
40.1	40.1	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
6.24	6.24	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
indicating	indicating	O	O	O	O
a	a	O	O	O	O
complete	complete	O	O	O	O
spasm	spasm	O	DISEASE	OTHERS	I
at	at	O	O	O	O
the	the	O	O	O	O
level	level	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
sphincter	sphincter	O	O	O	O
of	of	O	O	O	O
Oddi	oddi	O	O	O	O
.	.	O	O	O	O

Glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
infusion	infusion	O	O	O	O
completely	completely	O	O	O	O
normalized	normalized	O	O	O	O
the	the	O	O	O	O
prostigmine-morphine-induced	prostigmine-morphine-induced	O	O	O	O
alterations	alterations	O	O	O	O
in	in	O	O	O	O
these	these	O	O	O	O
quantitative	quantitative	O	O	O	O
parameters	parameters	O	O	O	O
(	(	O	O	O	O
TmaX	tmax	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
LP	lp	O	O	O	O
:	:	O	O	O	O
11.33	11.33	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1.13	1.13	O	O	O	O
;	;	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
HH	hh	O	O	O	O
:	:	O	O	O	O
18.88	18.88	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1.48	1.48	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
CBD	cbd	O	O	O	O
:	:	O	O	O	O
36.22	36.22	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1.92	1.92	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
T1/2	t1/2	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
LP	lp	O	O	O	O
:	:	O	O	O	O
28.21	28.21	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
1.83	1.83	O	O	O	O
;	;	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
HH	hh	O	O	O	O
:	:	O	O	O	O
33.42	33.42	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
3.10	3.10	O	O	O	O
;	;	O	O	O	O
and	and	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
CBD	cbd	O	O	O	O
:	:	O	O	O	O
41.66	41.66	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
6.33	6.33	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
suggesting	suggesting	O	O	O	O
an	an	O	O	O	O
effective	effective	O	O	O	O
sphincter-relaxing	sphincter-relaxing	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
These	these	O	O	O	O
results	results	O	O	O	O
provide	provide	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
effectiveness	effectiveness	O	O	O	O
of	of	O	O	O	O
glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
on	on	O	O	O	O
the	the	O	O	O	O
morphine-induced	morphine-induced	O	O	O	O
sphincter	sphincter	O	O	O	O
of	of	O	O	O	O
Oddi	oddi	O	O	O	O
spasm	spasm	O	DISEASE	OTHERS	I
in	in	O	O	O	O
humans	humans	O	O	O	O
.	.	O	O	O	O

Since	since	O	O	O	O
glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
is	is	O	O	O	O
able	able	O	O	O	O
to	to	O	O	O	O
overcome	overcome	O	O	O	O
even	even	O	O	O	O
the	the	O	O	O	O
drastic	drastic	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
morphine	morphine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
it	it	O	O	O	O
might	might	O	O	O	O
be	be	O	O	O	O
of	of	O	O	O	O
relevance	relevance	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
sphincter	sphincter	O	O	OTHERS	I
of	of	O	O	OTHERS	I
Oddi	oddi	O	O	OTHERS	I
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

